BC Advantage Funds invests in early-stage life science, technology, and clean tech companies.
Business Model: B2B
Revenue: $14.5M
Employees: 2-10
Address: 221 Esplanade W 410
City: North Vancouver
State: british columbia
Zip: V7M 3J3
Country: CA
BC Advantage Funds is a venture capital firm that caters to early stage life science, technology, and clean tech companies. In 2006, the company received the Canadian Venture Capital Association &s;Deal of the Year&s; award for achieving the highest realized return on a single investment (23.4X return on our investment in Aspreva Pharmaceuticals) of any venture capital firm in Canada. Furthermore, in the three years prior to its redemption (2006,2007, 2008), its Advantage Life Science Fund I provided the highest 5-year returns of any retail fund in Canada (Source: GlobeFund). Advantage most recent venture capital fund, the Advantage Structured Fund, was primarily raised and invested in the robust pre financial-crisis environment of 2004 – 2007. Since the financial crisis and recession of 2008 – 2009, we have had the challenging task of growing these businesses, keeping them financed despite difficult capital markets, and seeking profitable exits from the investments in a post financial-crisis environment characterized by few (if any) initial public offerings (IPOs), depressed activity in merger and acquisition (M&a;A) markets, and weakened valuations for emerging technology companies. In July, 2016, Advantage announced that its Board of Directors had concluded a review of strategic alternatives and determined that a liquidation and dissolution of the Company is the best alternative for maximizing shareholder value. The Board subsequently called an annual and special meeting of shareholders of the Company to approve a number of items, including the voluntary dissolution of the Company under Division 2 of Part 10 of the Business Corporations Act (British Columbia), the settlement of all of the assets of the Company on the Liquidation Trustee (as defined in the information circular in respect of the Meeting) on trust that the Trustee assume and pay all of the liabilities of the Company, and distribute all remaining assets of the Trust rateably to the shareholders of record. The Dissolution Resolution was approved by way of an ordinary and special resolution passed by a majority and at least two-thirds, respectively, of the votes cast by the Company’s shareholders the Meeting.
Contact Phone:
Contact Email:
Announced Date | Company | Transaction | Money Raised |
---|---|---|---|
7/2005 | MetroBridge Networks | Series B | - |
5/2008 | NPS | Venture Round | 9.7M |
11/2014 | Redlen Technologies | Venture Round | 2M |
2/2010 | Redlen Technologies | Venture Round | 7.8M |
1/2010 | Microvisk Technologies | Venture Round | 3.2M |
6/2007 | Aquinox Pharmaceuticals | Series A | 14.5M |
6/2008 | Inimex Pharmaceuticals | Series B | 22M |
9/2010 | Microvisk Technologies | Series A | 3.9M |
1/2007 | Mobidia Technology | Series A | 0 |
12/2007 | Zeugma Systems | Series B | 20M |
3/2009 | Zeugma Systems | Series C | 8.8M |
6/2007 | Contigo Systems | Series B | 3M |
4/2008 | Mobidia Technology | Venture Round | 9.3M |
7/2005 | Mobidia Technology | Series A | 6M |
4/2006 | GaleForce Solutions | Series B | 2.1M |
11/2014 | Redlen Technologies | Venture Round | 0 |
2/2010 | Redlen Technologies | Venture Round | 0 |
1/2010 | Microvisk Technologies | Venture Round | 0 |
3/2009 | Zeugma Systems | Series C | 0 |
6/2008 | Inimex Pharmaceuticals | Series B | 0 |
5/2008 | NPS | Venture Round | 0 |
4/2008 | Mobidia Technology | Venture Round | 0 |
12/2007 | Zeugma Systems | Series B | 0 |
6/2007 | Aquinox Pharmaceuticals | Series A | 0 |
6/2007 | Contigo Systems | Series B | 0 |
Name | Price |
---|
Name | Size | Announced Date |
---|